EDISON EQUITY RESEARCH - TRIMEL PHARMACEUTICALS
01 Décembre 2014 - 2:34PM
InvestorsHub NewsWire
EDISON EQUITY RESEARCH:
TRIMEL PHARMACEUTICALS - ENDO TO
PARTNER NATESTO
Trimel is partnering its Natesto intranasal gel testosterone
replacement therapy (TRT) product in the US and Mexico with Endo
Pharmaceuticals, receiving US$25m upfront and a tiered supply price
for manufacturing. Endo’s marketed portfolio of TRT products makes
it an ideal partner, and Trimel expects to be ready for commercial
manufacturing in Q115.
Trimel is a Canadian specialty pharmaceutical company. Natesto and
Tefina deliver testosterone through a bio-adhesive nasal gel drug
delivery technology platform, for male hypogonadism and female
orgasmic disorder (FOD), respectively. Estrace is being marketed
for HRT in Canada.
To view our full report, please click here:
http://www.edisoninvestmentresearch.com/research/report/trimel-pharmaceuticals6
Click here to view all of Edison
Investment Research’s published reports
Trilogy International Pa... (TSX:TRL)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Trilogy International Pa... (TSX:TRL)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Trilogy International Partners Inc (Toronto Stock Exchange): 0 recent articles
Plus d'articles sur Trimel Pharmaceuticals Corp